These efforts crystallized in 2016, when a patient with recurrent GBM treated with an IL13Ra2-targeting CAR T-cell experienced the regression of all intracranial and spinal tumors on imaging and remarkable clinical improvement [15]. Here, IL13RA2 is linked to glioblastoma.